Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com -- Boston Scientific (NYSE:BSX) posted second-quarter results that topped expectations, driven by strong organic growth and solid performance across key regions.
Adjusted EPS came in at $0.75, beating the $0.73 consensus. Revenue rose to $5.06 billion, up 22.8% year-over-year, exceeding the $4.89 billion forecast. On an organic basis, sales increased 17.4% year-over-year.
"This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth," said Mike Mahoney, chairman and CEO of Boston Scientific.
The company saw strong double-digit growth in the U.S. and Asia-Pacific of 30.7% and 18%, respectively, while EMEA and Latin America posted more modest gains. Emerging markets also contributed with healthy growth.
For the third quarter, it guided to EPS of $0.70 to $0.72, compared to expectations of $0.70.
Looking further ahead, Boston Scientific expects full-year 2025 EPS in the range of $2.95 to $2.99, above the $2.92 consensus.